| Name | Title | Contact Details |
|---|
Introducing life insurance made for living. Build your financial confidence with the power of protection and tax-deferred growth. Thats living Happy Everly After. Agency services provided by Everly, LLC, AR Insurance License # 3001180536 and CA Insurance License # 6004464. For a full list of states Everly is licensed to conduct business in, please refer to everlylife.com. Everly does not transact business in the state of New York. Something big is happening here. Do you fiercely challenge the way things have always been done? Are you ready to help change the way the world sees, buys and LIVES life insurance? Are you a tech-driven, data loving, customer obsessed, creative powerhouse looking for a new challenge? Sounds like we might be a good fit. Check out the open positions in our job board!
ZEA manufactures plant biologics for pharmaceutical uses providing wellness to the world. At ZEA, we are uprooting medicine by growing plants and using our proprietary technology to produce medicinal plant products and we offer superior data analytics in what is a $400 billion dollar market.
Somos una empresa internacional especializada en startups y empresas tech de LATAM. Acompañamos el crecimiento acelerado de los founders garantizándoles en cada etapa el cumplimiento de todos sus compromisos financieros, contables, impositivos y legales en cada país en el que operan. Nuestras soluciones contemplan servicios de compliance, impuestos internacionales, softlanding, CFO Services, transaction services y legal services. Nos caracterizamos por nuestra velocidad de respuesta, profesionalismo y calidad en la ejecución.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.